Back HCV Populations Children & Adolescents

FDA Approves Pegasys plus Ribavirin for Children with Chronic Hepatitis C

The U.S. Food and Drug Administration (FDA) has approved pegyalted interferon alfa-2a (brand name Pegasys) plus ribavirin (brand name Copegus) for previously untreated children and adolescents age 5-17 with chronic hepatitis C virus (HCV) infection. alt

Read more:

HCV Polymerase Inhibitor PSI-938 Gets Fast Track Status

The U.S. Food and Drug Administration (FDA) last week granted a "fast track" designation for PSI-938, an investigational nucleotide analog hepatitis C virus (HCV) polymerase inhibitor being developed by Pharmasset.alt

Read more: